Search clinical trials for: lapatinib

Total 1446 results

Novartis Pharmaceuticals
Breast International Group; SOLTI Breast Cancer Research Group

Completed

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)

Neoplasms, Breast

France, Spain, United Kingdom, Belgium, Argentina, Czechia, Germany, Italy, Norway, Russian Federation, Sweden, Taiwan, Hong Kong, Brazil, Hungary, India, Korea, Republic of, Pakistan, Peru, Romania, South Africa, Ukraine, Canada, Lit...
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

HER2-Positive Early Stage Breast Cancer

United States
Johns Hopkins University
Medical University of South Carolina; Children's Hospital of Philadelphia; Washington... and other collaborators

Completed

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease (HUPrevent)

Stroke | Sickle Cell Disease

United States
The First Affiliated Hospital of Kunming Medical...

Unknown

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Lung Cancer
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Hyundai Pharmaceutical Co., LTD.

Completed

To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers

Healthy Male
Peking University

Recruiting

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Esophageal Squamous Carcinoma

China
Leiden University Medical Center
Boehringer Ingelheim; Chordoma Foundation

Active, not recruiting

Afatinib in Locally Advanced and Metastatic Chordoma

Chordoma

United Kingdom, Netherlands, Italy
UNICANCER

Completed

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients (PREDICTOR)

Carcinoma, Squamous Cell of Head and Neck

France
Samsung Medical Center

Completed

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Non-small Cell Lung Cancer
Boehringer Ingelheim

Terminated

LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Head and Neck Neoplasms

Singapore, China, Korea, Republic of, Taiwan
Yonsei University

Unknown

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Squamous Cell Carcinoma of Esophagus

Korea, Republic of
Fujian Cancer Hospital

Not yet recruiting

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Gastric Adenocarcinoma | Advanced Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Washington University School of Medicine

Completed

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Relapsed, Refractory or Plateau Phase Multiple Myeloma

United States
Baylor Breast Care Center
M.D. Anderson Cancer Center

Terminated

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Breast Cancer

United States
Bristol-Myers Squibb

Completed

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

Liver Diseases

United States
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Chronic Myeloid Leukemia | Blast Crisis

Netherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
Federico II University
University of Bologna

Unknown

Evaluation of Response of Dasatinib to Treat Mastocytosis

Systemic Mastocytosis

Italy
Boehringer Ingelheim

Completed

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

Non-squamous, Non-Small Cell Lung Cancer

United States
Hellenic Cooperative Oncology Group

Completed

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Gene Mutation
Peking University

Not yet recruiting

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Esophageal Squamous Cell Carcinoma

China
Boehringer Ingelheim

Completed

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Carcinoma, Non-Small-Cell Lung

United States, Taiwan
European Organisation for Research and Treatment...

Suspended

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (REMNANT)

Non Small Cell Lung Cancer
Boehringer Ingelheim

Completed

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Neoplasms
Boehringer Ingelheim

Completed

Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours

Neoplasms

Belgium
Collin Blakely
Novartis

Recruiting

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer

United States
Chul Kim
Bristol-Myers Squibb; AstraZeneca; Walter Reed National Military Medical Center; Hackensack Meridian Health

Active, not recruiting

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Nonsmall Cell Lung Cancer | EGFR Gene Mutation

United States
Institute of Hematology & Blood Diseases Hospital

Withdrawn

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Relapsed AML | T(8;21) | C-KIT Mutation

China
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
Centre Leon Berard
National Cancer Institute, France

Recruiting

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)

Malignant Solid Neoplasms

France
University of Southern California
National Cancer Institute (NCI)

Terminated

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
GlaxoSmithKline

Completed

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer (CHERLOB)

Neoplasms, Breast

Italy, Germany, Poland
Xi'an International Medical Center Hospital

Not yet recruiting

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Breast Cancer

China
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Susan G. Komen Breast Cancer Foundation

Active, not recruiting

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Breast Cancer

United States
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Netherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland
Boehringer Ingelheim

Completed

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Breast Neoplasms

Hong Kong, Taiwan, United Kingdom, Russian Federation, India, Poland
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
GlaxoSmithKline

Completed

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Neoplasms, Breast

United States
Creighton University
Pfizer

Completed

Geodon (Ziprasidone) for Posttraumatic Stress Disorder

PTSD | Posttraumatic Stress Disorder | Post-Traumatic Stress Disorder

United States
Mabaret Al-Asafara Hospitals

Unknown

Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.

Drug Toxicity

Egypt
Third Military Medical University

Unknown

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx

Head and Neck Cancer

Belgium
Boehringer Ingelheim

Completed

The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer

Non-squamous, Non-Small Cell Lung Cancer

China
Michael Hopp
Boehringer Ingelheim

Active, not recruiting

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Non-squamous NSCLC

Germany
Tetraphase Pharmaceuticals, Inc.
PRA Health Sciences

Completed

Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers (BAL)

Healthy Subjects

United Kingdom
M.D. Anderson Cancer Center
Boehringer Ingelheim

Terminated

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Lung Cancer

United States
European Organisation for Research and Treatment...
Boehringer Ingelheim

Completed

Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

Belgium, Italy
Massachusetts General Hospital
Boehringer Ingelheim; University of Texas

Completed

Understanding Mechanisms of Acquired Resistance to BIBW2992

Non-small Cell Lung Cancer | EGFR Mutations

United States
Boehringer Ingelheim

Terminated

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Head and Neck Neoplasms

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Portugal, Russian Federation, Spain, Sweden, Switzerlan... and more

Search clinical trials for: lapatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations